Groundbreaking Technologies Fueling Novel Diagnostic and Precision Medicine Strategies

Groundbreaking Technologies Fueling Novel Diagnostic and Precision Medicine Strategies

RELEASE DATE
24-Jan-2020
REGION
Global
Research Code: D759-00-10-00-00
SKU: HC03260-GL-TA_24060

$950.00

Special Price $712.50 save 25 %

In stock
SKU
HC03260-GL-TA_24060

$950.00

$712.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) comprises groundbreaking advances across breast cancer screening, next generation sequencing, proteomics, and digital health platforms. The TOE also provides insights across innovative immunotherapy and precision medicine strategies.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Artificial intelligence, breast cancer, Google Health, next-generation sequencing, Omniome, proteomics, Seer, cardiovascular therapy, Anthos, digital neurology, Mindpax, Smart Gait, Dynamic Metrics, drug repurposing, Rejuvenate, Biomed, ProteoFormiX, multiple sclerosis, gut microbiome, Caelus Health, immunotherapy, Antagonis, Calypso, digital health, healthcare AI, Genome Biologics, MET Kinase, cancer therapy, OCTIMET, drug screening, Recursion Pharmaceuticals, digital cell biology, Berkeley Lights, nerve stimulation, Stimwave Technologies, stroke, Viz.ai, CATALOG, digital data, glioblastoma, MD Anderson Cancer Center, Fred Hutchinson Cancer Research Center, epitheloid sarcoma, Epizyme, autoimmune disorders, Alexion Pharmaceuticals, Lumasiran, Alnylam, small cell lung cancer, PharmaMar, Velano Vascular, blood draw, GlaxoSmithKline, myeloma

Table of Contents

Recent Innovations in Life Sciences, Health & Wellness

  • Artificial Intelligence Enabling Breast Cancer Screening
  • Advancing Next-generation Sequencing Technologies
  • Leveraging Proteomics for Health and Disease Studies
  • Targeted Therapy for Managing Cardiovascular Risks
  • Digital Tools for Neurological Disorders
  • Smart Gait Analysis System for Accurately Identify the Mobility Disorders
  • Repurposing Drugs for Delaying Age-related Disorders
  • Disease Analysis and Identification Through MS Platform
  • Gut Microbiota-based Prevention of Type-2 Diabetes
  • Unique Oligosaccharide Binding Protein Platform as Immunotherapy
  • Antibodies Therapeutics for Emerging Severe Pathologies
  • AI-powered Drug Disease Matching Platform
  • Highly Selective MET Kinase Inhibitors as Oncotherapy
  • Artificial Intelligence Empowering Drug Screening
  • Digital Cell Biology through Optofluidic Technology
  • Pain Relief through Wireless Nerve Stimulation
  • AI-driven Stroke Care Synchronization
  • Massive Digital Data Storage and Computation
  • Targeting CD73 to Solve Glioblastoma Tumor Resistance
  • Identifying the Key to Effective Immunotherapy
  • Novel Drug for Treatment of Epitheloid Sarcoma
  • FcRn As a Drug Target for IgG Autoimmune Disorders
  • Lumasiran Delivers in Phase 3 Clinical Study
  • Novel Drug for the Treatment of Small Cell Lung Cancer
  • Innovative Needle-free Blood Draw Device
  • BCMA-targeting Antibody-Drug Conjugate

Industry Influencers

  • Key Contacts
  • Key Contacts (continued)
  • Key Contacts (continued)
  • Key Contacts (continued)
  • Key Contacts (continued)
  • Key Contacts (continued)
  • Your F&S Thought Leader
Related Research
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) comprises groundbreaking advances across breast cancer screening, next generation sequencing, proteomics, and digital health platforms. The TOE also provides insights across innovative immunotherapy and precision medicine strategies. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Artificial intelligence, breast cancer, Google Health, next-generation sequencing, Omniome, proteomics, Seer, cardiovascular therapy, Anthos, digital neurology, Mindpax, Smart Gait, Dynamic Metrics, drug repurposing, Rejuvenate, Biomed, ProteoFormiX, multiple sclerosis, gut microbiome, Caelus Health, immunotherapy, Antagonis, Calypso, digital health, healthcare AI, Genome Biologics, MET Kinase, cancer therapy, OCTIMET, drug screening, Recursion Pharmaceuticals, digital cell biology, Berkeley Lights, nerve stimulation, Stimwave Technologies, stroke, Viz.ai, CATALOG, digital data, glioblastoma, MD Anderson Cancer Center, Fred Hutchinson Cancer Research Center, epitheloid sarcoma, Epizyme, autoimmune disorders, Alexion Pharmaceuticals, Lumasiran, Alnylam, small cell lung cancer, PharmaMar, Velano Vascular, blood draw, GlaxoSmithKline, myeloma
More Information
No Index No
Podcast No
Industries Healthcare
WIP Number D759-00-10-00-00
Is Prebook No
Ti Codes D759